ResMed (RMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Oct, 2026Executive summary
Annual meeting scheduled for Nov. 16, 2022 at 4:30 p.m. US Pacific Time; Nov. 17 at 11:30 a.m. Australian Eastern Time and 8:30 a.m. Singapore Time, via live webcast.
Voting matters and shareholder proposals
Board recommended votes For director elections, KPMG ratification, and advisory approval of named executive officer compensation.
Board of directors and corporate governance
Ten directors nominated to serve until the 2023 annual meeting and until successors are elected and qualified: Carol Burt, Jan De Witte, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Richard Sulpizio, Desney Tan, and Ronald Taylor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ResMed
- Revenue rose 7% core CC, EPS 14%, and shareholder returns topped $1.0B.RMD
Q1 2027 - Ten director elections, KPMG ratification, and advisory votes anchor the ballot.RMDProxy Filing
- Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMDProxy Filing
- Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMDProxy Filing
- 2026 saw strong growth, strategic investments, and enhanced sustainability and governance.RMDStewardship presentation
- FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMDCorporate presentation
- Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook.RMDMorgan Stanley 24th Annual Global Healthcare Conference
- FY26 revenue grew 8% to $5.7B, with strong margins, digital innovation, and increased shareholder returns.RMDCorporate presentation
- Record FY26 growth, margin expansion, and $1.85B+ FY27 capital returns planned.RMDQ4 2026